A single dose of MDMA prevents trauma-fueled drinking in genetically prone rats

A recent experiment in rats suggests that MDMA can prevent the increase in alcohol consumption that often follows a traumatic event, particularly in subjects genetically predisposed to drink heavily. The findings indicate that the drug alters the way fear is expressed in the moment rather than permanently strengthening the brain’s ability to unlearn fear memories. The research was published in Neuropsychopharmacology.

Post-traumatic stress disorder, or PTSD, is a mental health condition triggered by experiencing or witnessing a terrifying event. Many individuals with PTSD also develop alcohol use disorder, drinking to cope with intrusive memories and emotional distress. This relationship is complex and mutually reinforcing, as chronic alcohol use dysregulates stress systems in the brain, often worsening trauma symptoms over time.

To treat PTSD, therapists often rely on fear extinction. This is a learning process where an individual is repeatedly exposed to trauma-related cues in a safe environment until those cues no longer trigger a fear response. A 2015 study covered by PsyPost in 2015 indicated that administering MDMA prior to this exposure process helped accelerate fear extinction in mice.

Building on such animal research, early human studies suggest that MDMA-assisted therapy might ease symptoms of both PTSD and addiction, including a small, uncontrolled 2021 pilot study that found the approach safe and promising for treating alcohol use disorder. At the same time, scientists recognize that the connection between fear and alcohol is strongly influenced by genetics. For example, a 2016 study provided evidence that rodents selectively bred to prefer alcohol also display exaggerated fear responses, pointing to an innate biological link between anxiety and drinking.

Despite this progress, it was unknown whether giving MDMA specifically to treat trauma-like symptoms would also reduce a later urge to drink in subjects actively displaying both behaviors. The research, led by Kade L. Huckstep, Billi Newton, and Leigh C. Walker of the Florey Institute of Neuroscience and Mental Health and the University of Melbourne, set out to see if MDMA could curb trauma-triggered drinking in genetically prone animals.

“One of the challenges with clinical trials of MDMA-assisted therapy is determining how much of the observed benefit is attributable to MDMA itself,” Walker, deputy lead of Mental Health Research and Group Head of the Hormone and Behaviour Laboratory at the Florey Institute, told PsyPost. “Because the subjective effects of MDMA are very noticeable, effective blinding can be difficult, and factors such as expectancy and the therapeutic setting may also influence outcomes.”

To overcome this, the researchers aimed to mirror real-world research. “We wanted to develop a rodent model that, as closely as possible, reflected ongoing clinical trials investigating MDMA in people with co-occurring PTSD and alcohol use disorder (e.g., MPATHY),” Walker explained. “This allowed us to examine the effects of MDMA in a highly controlled setting, without expectancy or placebo effects, and determine whether MDMA itself alters fear-related behavior and alcohol consumption.”

“Importantly, we also wanted to identify any unintended effects, e.g., whether MDMA could worsen fear-related behavior or alcohol consumption under particular conditions, an important factor relevant to our clinical collaborators conducting the corresponding human trials,” she added.

To explore this, the team used 53 Indiana alcohol-preferring rats, a strain selectively bred to voluntarily consume high amounts of alcohol, and 64 Wistar rats, a standard outbred strain. Both male and female rats were used. The animals first underwent auditory fear conditioning, a procedure where a specific tone is repeatedly paired with a mild, one-second electrical foot shock. This teaches the animals to associate the sound with an aversive event, causing them to freeze in place whenever they hear it. A separate control group heard the tone but received no shocks.

Following this conditioning, all the rats were given intermittent access to a solution of twenty percent alcohol and water for six weeks. This allowed them to develop a voluntary drinking habit. Afterward, the researchers removed the alcohol for three weeks to simulate a period of abstinence.

At the end of the abstinence period, the animals received an injection of either MDMA or a simple saline solution. Thirty minutes later, they were placed into a fear extinction session where the tone was played repeatedly without any foot shocks. The following day, the rats underwent a drug-free test to see how well they remembered the extinction learning. Finally, they were given free access to alcohol again for eight sessions to measure their post-treatment drinking behavior.

The researchers found that the initial fear conditioning modestly increased later alcohol consumption, but only in the genetically vulnerable Indiana alcohol-preferring rats. The Wistar rats learned to fear the tone just as strongly, but this distressing experience did not drive them to drink more alcohol than their unshocked counterparts. This finding suggests that trauma-like stress drives increased drinking specifically when a genetic predisposition is present.

When the rats received MDMA before the fear extinction session, their immediate reactions to the tone changed. The drug initially reduced their freezing behavior early in the session. However, as the session went on, the two strains reacted differently. The Indiana alcohol-preferring rats ended up freezing more overall while on the drug, while the female Wistar rats froze less.

Despite these in-the-moment changes, MDMA did not improve how well the rats remembered the safety of the tone the following day. During the drug-free recall test, the MDMA-treated rats showed no better fear extinction than those given the saline solution. However, the MDMA treatment had a modest protective effect against trauma-induced drinking. In the Indiana alcohol-preferring rats that had experienced fear conditioning, those treated with MDMA did not show the trauma-related escalation in alcohol intake that was seen in the saline group.

“For us, the most important finding was not necessarily how large the effect was, but that it differed depending on the animals we studied,” Walker noted. “MDMA reduced drinking in rats that were particularly vulnerable to high alcohol use and more stress sensitive — and this effect persisted over 3 weeks. It will be interesting to see whether a similar pattern emerges in clinical trials, and whether particular groups of people may benefit more from MDMA-assisted therapy than others.”

To verify whether the drug’s effects on fear depended on the animals’ six-week history with alcohol, the team tested an additional group of 25 Indiana alcohol-preferring rats. These animals went through the same conditioning, MDMA, and extinction procedures, but went straight to extinction the day after conditioning, skipping the weeks of drinking and abstinence.

In this alcohol-naive group, MDMA still altered their immediate fear expression during the extinction session without improving their drug-free memory of it the next day. When these rats were introduced to alcohol for the first time after treatment, the MDMA-treated males showed lower initial consumption than those given saline, but this reduction was short-lived, and their overall drinking quickly matched the control group. This indicates that MDMA’s most reliable benefit in this model is blocking the long-term escalation of drinking that results from a combination of trauma and prior alcohol experience.

This decoupling of fear and drinking behavior was an unexpected outcome for the team. “We were surprised that MDMA’s effects on alcohol consumption did not seem to be directly linked to its effects on fear,” Walker said. “We initially thought that reducing fear responses might also reduce subsequent drinking, but the two effects appeared to be separate. This suggests that MDMA may influence alcohol use through other mechanisms that we still need to understand.”

As with all research, there are some caveats to consider. The study measured voluntary alcohol consumption under a limited-access schedule and did not measure blood alcohol concentrations, meaning the shifts in drinking might not reflect intoxication-level binges. The team also tested a single dose of MDMA given thirty minutes before extinction. Different doses or timing schedules might yield varying effects on learning and alcohol consumption.

“The main caveat is that this was a study in rats, and our findings should not be taken to mean that MDMA will reduce alcohol use in people,” Walker cautioned. “What the study does show is that responses to MDMA can vary considerably depending on the individual, including their vulnerability to heavy drinking and their sex. Understanding these differences will be important as we learn more from ongoing clinical trials. If so, we can use this model to delve into the mechanisms that may be responsible.”

There are a few other things to keep in mind regarding how these animal behaviors translate to humans. Animal models of fear extinction only capture a narrow aspect of trauma therapy. They cannot replicate the complex relational and emotional support that defines MDMA-assisted psychotherapy in clinical settings.

Moving forward, the researchers hope to use this model to investigate the biological foundations of the treatment. “We would like to understand the brain and biological mechanisms that drive the effects of MDMA and MDMA-assisted therapy,” Walker said. “Ultimately, this could help identify who is most likely to benefit from treatment. Understanding how these treatments actually work may also help move the conversation beyond some of the stigma or fear associated with taking drugs such as MDMA during therapy, allowing their potential benefits and risks to be considered based on scientific evidence.”

“One important lesson from this study is the need to better reflect human diversity in preclinical research,” she added. “By studying co-occurring conditions such as trauma and problematic alcohol use, and considering biological factors such as sex and genetic vulnerability from the outset, we can uncover differences that might otherwise be missed. Keeping these factors at the forefront may help us better understand why treatments work for some people but not others, and ultimately improve how findings from animal studies translate to the clinic.”

The study, “MDMA alters fear extinction, and reduces alcohol consumption in inbred alcohol preferring iP rats but not outbred Wistar rats,” was authored by Kade L. Huckstep, Billi Newton, Grace Bailey, Annai Charlton, Amy J. Pearl, Xavier J. Maddern, Robyn M. Brown, Gavan P. McNally, Dan I. Lubman, Shalini Arunogiri, Kirsten C. Morley, Erin J. Campbell, Andrew J. Lawrence, and Leigh C. Walker.